Evaluation of non-classical analytes in nonhuman primate cytokine release assays

SOT 2025 -- The various formats of cytokine release assays (CRAs) are in vitro assays utilizing nonhuman primate (NHP) immune cells representing a novel, inexpensive and rapid means of evaluating the safety profile of potential therapeutics prior to preclinical animal studies. Classically, CRA design across all formats focused almost exclusively on the evaluation of analytes such as IFNγ, IL-2, IL-6 and TNFα to assess the risk of eliciting cytokine release syndrome (CRS) in vivo. However, when considering an in vitro assay to evaluate potential immunomodulation of a therapeutic on NHP immune cells, the inclusion of a wider array of analytes can generate not only important safety data but provide key mechanistic insights as well. In the current study, we evaluated several prevalent positive control compounds used in CRAs in a commonly utilized CRA format – liquid phase stimulation of NHP peripheral blood mononuclear cells (PBMCs). These positive controls were chosen for their ability to stimulate production of cytokines and chemokines outside those traditionally included in CRAs.

Using computational fluid dynamics to estimate the efficiency of delivery by changing the position of the rat snout and airflow received using an inhalation directed flow chamber

SOT 2025 -- Inhalation administration is a common dose route used in nonclinical development for delivering drugs to the lungs. The standard approach is to evaluate drug safety in both a rodent and non-rodent species. With the continued use of both New Chemical Entities (NCEs) and biopharmaceuticals, rats continue to be the rodent species of choice. The standard method for delivering the aerosol to rats is using a snout-only inhalation chamber called a direct flow chamber. During the exposure period, the rats are restrained in plastic clear restraint tubes. Consistent dosing is pivotal in ensuring effective study conduct and data interpretation to draw accurate conclusions about the safety of the test article; however, it is commonly observed that the animal and animal snout frequently move during the dosing period and require adjustment where possible. Furthermore, there is anecdotal evidence that the animal-to-animal variation with the dose received is greater for the inhalation route of administration compared to other routes such as oral and intravenous. In this study, Labcorp wanted to establish whether the position of the snout relative to the end of the aerosol chamber delivery tube contributed towards this perceived animal-to-animal dose variability.

Development of a mouse bile-duct cannulated model for use in DMPK studies

SOT 2025 -- The use of surgical models can provide valuable information on the absorption and metabolism of new drug candidates over a continual time course. The mouse (Mus musculus), including genetically modified models, is a commonly used laboratory animal. In preclinical safety assessment studies (toxicology, metabolism, pharmacology and pharmacokinetic studies), the mouse is the most common alternative rodent species to the rat. The mouse can offer physiological or metabolic characteristics that are more relevant to the human condition than the rat. The objectives of this initiative were to: Further develop a mouse bile duct-cannulated (BDC) model and characterise the routes and rates of excretion of total radioactivity in urine, faeces and bile, following oral administration of a radiolabelled test article (5 mL/kg) to intact and biliary cannulated mice.

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and OPKO Health,

Navy Veteran to Advocate: A Life-Changing Genetic Testing Journey

Dan "Dry Dock" Shockley served on multiple ships before he retired from his 22-year career in the United States Navy. That’s how he got his nickname, “Dry Dock,” traveling to 22 countries all over the world, docking in places like Singapore, Qatar, and Spain. But after settling into retirement on Oahu, he found himself on a new, unexpected journey.

Improving hospital performance with real-time analytics: a Labcorp and Ochsner Health case study

How Labcorp's Visiun analytics platform helped Ochsner Health improve efficiency, reduce costs and enhance patient outcomes. 

The 2025 AAN Annual Meeting

Advancing breakthroughs for neurodegenerative diseases requires asking complex questions. Labcorp is proud to present three new abstracts at The 2025 AAN Annual Meeting on how new blood biomarkers can bring clarity to diagnosis and treatment decisions.

Labcorp STI Patient Self-Collection Video Instructions